Clinical Trial Update: Herombopag Treated T-DM1 Induced Platelet Reduction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating herombopag to treat thrombocytopenia induced by T-DM1, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Herombopag (herombopag)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Thrombocytopenia | Phase 2 | Status: RECRUITING